Marina Sayuri Nogueira

Dr. Marina Sayuri Nogueira

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Food Research International
Verified
Journal Article
Closed access
TCTalita A. Comunian
Talita A. Comunian
MBMickaël R.G. Boillon
Mickaël R.G. Boillon
MTMarcelo Thomazini
Marcelo Thomazini
MNMarina Sayuri Nogueira
Marina Sayuri Nogueira
ICInar Alves de Castro
Inar Alves de Castro
Carmen Silvia Favaro-TrindadeCarmen Silvia Favaro-Trindade
Carmen Silvia Favaro-Trindade

Verified
Journal Article
Open access
PDF file
SYSara Crespo Yanguas
Sara Crespo Yanguas
TSTereza C. Da Silva
Tereza C. Da Silva
IPIsabel V. A. Pereira
Isabel V. A. Pereira
JWJoost Willebrords
Joost Willebrords
MMMichaël Maes
Michaël Maes
Mathieu VinkenMathieu Vinken
Mathieu Vinken
Although a plethora of signaling pathways are known to drive the activation of hepatic stellate cells in liver fibrosis, the involvement of connexin-based communication in this process remains elusive. Connexin43 expression is enhanced in activated hepatic stellate cells and constitutes the molecular building stone of hemichannels and gap junctions. While gap junctions support intercellular communication, and hence the maintenance of liver homeostasis, hemichannels provide a circuit for extracellular communication and are typically opened by pathological stimuli, such as oxidative stress and inflammation. The present study was set up to investigate the effects of inhibition of connexin43-based hemichannels and gap junctions on liver fibrosis in mice. Liver fibrosis was induced by administration of thioacetamide to Balb/c mice for eight weeks. Thereafter, mice were treated for two weeks with TAT-Gap19, a specific connexin43 hemichannel inhibitor, or carbenoxolone, a general hemichannel and gap junction inhibitor. Subsequently, histopathological analysis was performed and markers of hepatic damage and functionality, oxidative stress, hepatic stellate cell activation and inflammation were evaluated. Connexin43 hemichannel specificity of TAT-Gap19 was confirmed in vitro by fluorescence recovery after photobleaching analysis and the measurement of extracellular release of adenosine-5′-triphosphate. Upon administration to animals, both TAT-Gap19 and carbenoxolone lowered the degree of liver fibrosis accompanied by superoxide dismutase overactivation and reduced production of inflammatory proteins, respectively. These results support a role of connexin-based signaling in the resolution of liver fibrosis, and simultaneously demonstrate the therapeutic potential of TAT-Gap19 and carbenoxolone in the treatment of this type of chronic liver disease.

15 August 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JWJoost Willebrords
Joost Willebrords
BCBruno Cogliati
Bruno Cogliati
IPIsabel Veloso Alves Pereira
Isabel Veloso Alves Pereira
TSTereza Cristina da Silva
Tereza Cristina da Silva
SYSara Crespo Yanguas
Sara Crespo Yanguas
Mathieu VinkenMathieu Vinken
Mathieu Vinken
While gap junctions mediate intercellular communication and support liver homeostasis, connexin hemichannels are preferentially opened by pathological stimuli, including inflammation and oxidative stress. The latter are essential features of non-alcoholic steatohepatitis. In this study, it was investigated whether connexin32 and connexin43 hemichannels play a role in non-alcoholic steatohepatitis. Mice were fed a choline-deficient high-fat diet or normal diet for 8 weeks. Thereafter, TAT-Gap24 or TAT-Gap19, specific inhibitors of hemichannels composed of connexin32 and connexin43, respectively, were administered for 2 weeks. Subsequently, histopathological examination was carried out and various indicators of inflammation, liver damage and oxidative stress were tested. In addition, whole transcriptome microarray analysis of liver tissue was performed. Channel specificity of TAT-Gap24 and TAT-Gap19 was examined in vitro by fluorescence recovery after photobleaching analysis and measurement of extracellular release of adenosine triphosphate. TAT-Gap24 and TAT-Gap19 were shown to be hemichannel-specific in cultured primary hepatocytes. Diet-fed animals treated with TAT-Gap24 or TAT-Gap19 displayed decreased amounts of liver lipids and inflammatory markers, and augmented levels of superoxide dismutase, which was supported by the microarray results. These findings show the involvement of connexin32 and connexin43 hemichannels in non-alcoholic steatohepatitis and, simultaneously, suggest a role as potential drug targets in non-alcoholic steatohepatitis.

1 March 2018 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
JWJoost Willebrords
Joost Willebrords
MMMichaël Maes
Michaël Maes
IPIsabel Veloso Alves Pereira
Isabel Veloso Alves Pereira
TSTereza Cristina da Silva
Tereza Cristina da Silva
VGVeronica Mollica Govoni
Veronica Mollica Govoni
Mathieu VinkenMathieu Vinken
Mathieu Vinken

20 May 2016 in British Journal of Nutrition
Verified
Journal Article
Closed access
PDF file
MNMarina Sayuri Nogueira
Marina Sayuri Nogueira
MKM. C. Kessuane
M. C. Kessuane
ALA. A. B. Lobo Ladd
A. A. B. Lobo Ladd
FLF. V. Lobo Ladd
F. V. Lobo Ladd
BCBruno Cogliati
Bruno Cogliati
ICInar Castro
Inar Castro
The effect of oxidised fatty acids on atherosclerosis progression is controversial. Thus, our objective was to evaluate the effect of long-term consumption of weakly oxidised PUFA from flaxseed oil on oxidative stress biomarkers of LDL-receptor(−/−) mice. To test our hypothesis, mice were separated into three groups. The first group received a high-fat diet containing fresh flaxseed oil (CONT−), the second was fed the same diet prepared using heated flaxseed oil (OXID), and the third group received the same diet containing fresh flaxseed oil and had diabetes induced by streptozotocin (CONT+). Oxidative stress, aortic parameters and non-alcoholic fatty liver disease were assessed. After 3 months, plasma lipid profile, glucose levels, body weight, energy intake and dietary intake did not differ among groups. Likewise, oxidative stress, plasma malondialdehyde (MDA), hepatic MDA expressed as nmol/mg portion (ptn) and antioxidant enzymes did not differ among the groups. Hepatic linoleic acid, α-linolenic acid, arachidonic acid and EPA acid declined in the OXID and CONT+ groups. Aortic wall thickness, lumen and diameter increased only in the OXID group. OXID and CONT+ groups exhibited higher concentrations of MDA, expressed as μmol/mg ptn per %PUFA, when compared with the CONT− group. Our results suggest that ingestion of oxidised flaxseed oil increases hepatic MDA concentration and is potentially pro-atherogenic. In addition, the mean MDA value observed in all groups was similar to those reported in other studies that used xenobiotics as oxidative stress inducers. Thus, the diet applied in this study represents an interesting model for further research involving antioxidants.

1 May 2018 in Molecular Metabolism
Verified
Journal Article
Open access
BSBianca Scolaro
Bianca Scolaro
MNMarina Sayuri Nogueira
Marina Sayuri Nogueira
APAline Paiva
Aline Paiva
ABAdriana Bertolami
Adriana Bertolami
LBLucia P. Barroso
Lucia P. Barroso
ICInar Castro
Inar Castro
Statin intolerance, whether real or perceived, is a growing issue in clinical practice. Our aim was to evaluate the effects of reduced-dose statin therapy complemented with nutraceuticals. First phase: Initially, 53 type 2 diabetic statin-treated patients received a supplementation with fish oil (1.7 g EPA + DHA/day), chocolate containing plant sterols (2.2 g/day), and green tea (two sachets/day) for 6 weeks. Second phase: "Good responders" to supplementation were identified after multivariate analysis (n = 10), and recruited for a pilot protocol of statin dose reduction. "Good responders" were then provided with supplementation for 12 weeks: standard statin therapy was kept during the first 6 weeks and reduced by 50% from weeks 6-12. First phase: After 6 weeks of supplementation, plasma LDL-C (-13.7% ± 3.7, P = .002) and C-reactive protein (-35.5% ± 5.9, P = .03) were reduced. Analysis of lathosterol and campesterol in plasma suggested that intensity of LDL-C reduction was influenced by cholesterol absorption rate rather than its synthesis. Second phase: no difference was observed for plasma lipids, inflammation, cholesterol efflux capacity, or HDL particles after statin dose reduction when compared to standard therapy. Although limited by the small sample size, our study demonstrates the potential for a new therapeutic approach combining lower statin dose and specific dietary compounds. Further studies should elucidate "good responders" profile as a tool for personalized medicine. This may be particularly helpful in the many patients with or at risk for CVD who cannot tolerate high dose statin therapy. ClinicalTrials.gov, NCT02732223.